Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioGaia AB ( ($SE:BIOG.B) ) just unveiled an announcement.
BioGaia AB has announced the results of a study published in the European Journal of Pediatrics, demonstrating that their patented probiotic strain, Limosilactobacillus reuteri DSM 17938, effectively prevents antibiotic-associated diarrhea (AAD) in children. The PEARL Study, a large-scale, multi-center, randomized, placebo-controlled clinical trial, showed significant reductions in AAD incidence among children treated with the probiotic, particularly those with acute otitis media. This finding strengthens BioGaia’s position as a leader in probiotics, highlighting the potential of L. reuteri DSM 17938 as a safe adjunct to antibiotic therapy in pediatric care, thus supporting their mission to promote health through the microbiome.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK115.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia AB is a company specializing in the development and production of probiotics. Their primary focus is on creating evidence-based probiotic solutions that promote health by maintaining gut microbiota balance. BioGaia is recognized for its commitment to enhancing health through microbiome research and innovation.
YTD Price Performance: 0.28%
Average Trading Volume: 180,646
Technical Sentiment Signal: Buy
Current Market Cap: SEK10.72B
See more insights into BIOG.B stock on TipRanks’ Stock Analysis page.